Neogenomics (NEO) Long-Term Investments (2020 - 2021)

Neogenomics (NEO) posted Long-Term Investments of $29.6 million for Q1 2021, little changed quarter-over-quarter from $29.6 million in Q4 2020.

Neogenomics (NEO) Long-Term Investments (2020 - 2021) Analysis & Trends

Neogenomics (NEO) has reported Long-Term Investments for 2 consecutive years, with $29.6 million the latest figure, recorded in Q1 2021.

Long-Term Investments for Q1 2021 came in at $29.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $29.6 million (changed N/A YoY), and the FY2020 annual result was $29.6 million, changed N/A from the prior year.
Long-Term Investments was $29.6 million for Q1 2021 at Neogenomics, roughly flat from $29.6 million in the prior quarter.
Over five years, Long-Term Investments peaked at $29.6 million in Q4 2020 and troughed at $13.1 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn	-
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn	-
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn	-
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn	-
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn	136.00 Mn
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn	357.00 Mn
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn	-
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn	-
10	Neogenomics	1.93 Bn	1.79 Bn	80.86 Mn	-

Download Data